Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Belinda E Kiely"'
Publikováno v:
JMIR Cancer, Vol 9, p e43609 (2023)
BackgroundScan-associated anxiety (or “scanxiety”) is commonly experienced by people having cancer-related scans. Social media platforms such as Twitter provide a novel source of data for observational research. ObjectiveWe aimed to identify pos
Externí odkaz:
https://doaj.org/article/64dc9c71e3234b8fb1f0af2ff638dc8f
Publikováno v:
BMJ Open, Vol 11, Iss 5 (2021)
Objectives To identify available literature on prevalence, severity and contributing factors of scan-associated anxiety (‘scanxiety’) and interventions to reduce it.Design Systematic scoping review.Data sources Ovid MEDLINE, Ovid EMBASE, Ovid Psy
Externí odkaz:
https://doaj.org/article/47b3139e699746f7ae46ace55c30c6b8
Autor:
Benjamin Daniels, Federico Girosi, Hanna Tervonen, Belinda E Kiely, Sarah J Lord, Nehmat Houssami, Sallie-Anne Pearson
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0198152 (2018)
BACKGROUND:Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines. As therapeuti
Externí odkaz:
https://doaj.org/article/c8e82951184b460b96c8f0d2540c006d
Autor:
Robert Stein, Andreas Makris, Iain Macpherson, Luke Hughes-Davies, Andrea Marshall, Georgina Dotchin, David A. Cameron, Belinda E. Kiely, Caroline Wilson, Anne Armstrong, Helena M. Earl, Christopher J. Poole, Janice Tsang, Bjørn Naume, Daniel Rea, Hege Ohnstad, Peter S. Hall, Stuart A. McIntosh, Bethany Shinkins, Christopher McCabe, Adrienne Morgan, John MS Bartlett, Janet A. Dunn
Publikováno v:
Cancer Research. 83:OT3-32
Background: Multi-parameter tumor gene expression assays (MPAs) are used to estimate individual patient risk and guide chemotherapy use in hormone-sensitive, HER2-negative early breast cancer. The TAILORx trial supports MPA use in a node-negative pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4608f40c8058d8e5d8f14823e19e5775
https://doi.org/10.1158/1538-7445.sabcs22-ot3-32-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-32-01
Autor:
Sheau Wen Lok, Richard De Boer, Sally Baron‐Hay, Peter Button, Bianca Devitt, Benjamin C. Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E. Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs
Publikováno v:
International Journal of Cancer. 152:267-275
The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the prognosis of patients with early st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11e7f60ca3d7d3f3a56071b69dd458b
https://doi.org/10.1002/ijc.34245
https://doi.org/10.1002/ijc.34245
Autor:
Sharon H. Nahm, Martin R. Stockler, Andrew J. Martin, Peter Grimison, Peter Fox, Rob Zielinski, Geoffrey AT. Hawson, Martin HN. Tattersall, Belinda E. Kiely
Publikováno v:
Supportive Care in Cancer. 30:7763-7772
Aim To evaluate a web-based tool for estimating and explaining three scenarios for expected survival time to people with advanced cancer (patients), their family members (FMs), and other healthcare professionals (HCPs). Methods Thirty-three oncologis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca9f5a5272d58a61f60b3ded6d1d5261
https://doi.org/10.1007/s00520-022-07167-3
https://doi.org/10.1007/s00520-022-07167-3
Autor:
Sheau Wen Lok, Richard De Boer, Sallt Baron-Hay, Peter Button, Bianca Devitt, Benjamin Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter GIbbs
Publikováno v:
Cancer Research. 82:P2-13
BACKGROUND Adding pertuzumab to trastuzumab in patients (pts) with HER2+ breast cancer improves pathological complete response (pCR) rates. Pertuzumab + trastuzumab + chemotherapy is approved in Australia as neoadjuvant therapy in early stage (>2 cm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbf237de6e3b145fc556c4016fa144d5
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-38
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-38
BACKGROUND Scan-associated anxiety (or “scanxiety”) is commonly experienced by people having cancer-related scans. Social media platforms such as Twitter provide a novel source of data for observational research. OBJECTIVE We aimed to identify po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67f14223684be7144904b40c4cc46910
https://doi.org/10.2196/preprints.43609
https://doi.org/10.2196/preprints.43609
Autor:
Maren Paus Reinertsen, Heidi Liland, Ala Jabri Haug, Jordi Deu Martinez, Martin R Stockler, Guro Aune, Belinda E Kiely, Torbjørn Paulsen, Ingvild Vistad, Kristina Lindemann
Publikováno v:
Palliative care.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9539f18b0d1566ed7d932a55023fc721
https://doi.org/10.1136/ijgc-2022-esgo.781
https://doi.org/10.1136/ijgc-2022-esgo.781
Autor:
Prunella Blinman, Haryana M. Dhillon, Belinda E Kiely, Mohsen Shafiei, Kay Xu, Christopher L. Brown, Kim Tam Bui
Publikováno v:
Supportive Care in Cancer. 30:511-519
Scan-associated anxiety (‘scanxiety’) is a problem for people with advanced cancer. We aimed to determine the prevalence, severity and associations of scanxiety in this population. People with advanced cancer and a computed tomography scan within
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efd871218b60c30695c9ef894fea223c
https://doi.org/10.1007/s00520-021-06454-9
https://doi.org/10.1007/s00520-021-06454-9